CL2019001938A1 - Composiciones probióticas y usos de las mismas. - Google Patents

Composiciones probióticas y usos de las mismas.

Info

Publication number
CL2019001938A1
CL2019001938A1 CL2019001938A CL2019001938A CL2019001938A1 CL 2019001938 A1 CL2019001938 A1 CL 2019001938A1 CL 2019001938 A CL2019001938 A CL 2019001938A CL 2019001938 A CL2019001938 A CL 2019001938A CL 2019001938 A1 CL2019001938 A1 CL 2019001938A1
Authority
CL
Chile
Prior art keywords
lactobacillus
prevention
probiotic compositions
treatment
combination
Prior art date
Application number
CL2019001938A
Other languages
English (en)
Inventor
Daniel Agardh
Ahrén Irini Lazou
Lars Niklas Larsson
Original Assignee
Probi Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1700542.2A external-priority patent/GB201700542D0/en
Priority claimed from GBGB1709731.2A external-priority patent/GB201709731D0/en
Application filed by Probi Ab filed Critical Probi Ab
Publication of CL2019001938A1 publication Critical patent/CL2019001938A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A AL MENOS UNA CEPA PROBIÓTICA DE LACTOBACILLUS PARA SU USO EN UN SUJETO PARA LA PREVENCIÓN Y/O EL TRATAMIENTO DE LA AUTOINMUNIDAD DE LA ENFERMEDAD CELIACA (AEC), O PARA SU USO EN PREVENCIÓN Y/O TRATAMIENTO DE LA ENFERMEDAD CELÍACA (CD). UNA COMPOSICIÓN PREFERIDA PARA SU USO DE ACUERDO CON LA INVENCIÓN ES UNA COMPOSICIÓN QUE COMPRENDE UNA COMBINACIÓN DE LACTOBACILLUS PARACASEI Y LACTOBACILLUS PLANTARUM, ESPECIALMENTE L. PARACASEI 8700:2 (DSM 13434) EN COMBINACIÓN CON L. PLANTARUM HEAL 9 (DSM 15312).
CL2019001938A 2017-01-12 2019-07-11 Composiciones probióticas y usos de las mismas. CL2019001938A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1700542.2A GB201700542D0 (en) 2017-01-12 2017-01-12 Probiotic compositions and uses thereof
GBGB1709731.2A GB201709731D0 (en) 2017-06-19 2017-06-19 Probiotic compositions and uses thereof

Publications (1)

Publication Number Publication Date
CL2019001938A1 true CL2019001938A1 (es) 2019-09-27

Family

ID=61386800

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001938A CL2019001938A1 (es) 2017-01-12 2019-07-11 Composiciones probióticas y usos de las mismas.

Country Status (14)

Country Link
US (1) US11166993B2 (es)
EP (1) EP3568144B1 (es)
JP (1) JP7089523B2 (es)
KR (1) KR102500496B1 (es)
CN (1) CN110177561B (es)
AU (1) AU2018207946B2 (es)
BR (1) BR112019014418A2 (es)
CA (1) CA3049624A1 (es)
CL (1) CL2019001938A1 (es)
MX (1) MX2019008292A (es)
MY (1) MY195253A (es)
PH (1) PH12019501629A1 (es)
RU (1) RU2763311C2 (es)
WO (1) WO2018130667A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076615A2 (en) * 2003-02-27 2004-09-10 Bioneer A/S Immunomodulating probiotic compounds
WO2006097949A1 (en) * 2005-03-16 2006-09-21 Actial Farmacêutica, Lda. Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
CN101384269B (zh) * 2005-10-06 2012-11-14 普罗比公司 乳酸杆菌用于治疗病毒感染的用途
US8420376B2 (en) * 2005-10-06 2013-04-16 Probi Ab Use of Lactobacillus for treatment of virus infections
WO2007108763A1 (en) * 2006-03-17 2007-09-27 Probac Ab Use of lactobacillus strains for promoting immunotolerance in autoimmune disease
EP1996696B1 (en) * 2006-03-17 2016-12-21 Probi Aktiebolag Thermostable lactobacillus strains
CA3042826A1 (en) 2008-11-30 2010-06-03 Immusant, Inc. Compositions and methods for treatment of celiac disease
EP2581461B1 (en) * 2011-10-14 2014-09-24 GenMont Biotech Incorporation Composition and use of lactobacillus paracasei strain GMNL-133 in treating atopic dermatitis or other allergic diseases
DK3351554T3 (da) * 2012-06-18 2021-08-30 Heinz Co Brands H J Llc Glutenrelaterede forstyrrelser
DK2981274T3 (da) * 2013-04-03 2020-07-06 Probi Ab Probiotiske stammer til anvendelse ved behandling eller forebyggelse af osteoporose
WO2016083450A2 (en) * 2014-11-25 2016-06-02 Stichting Top Institute Food And Nutrition New probiotic and new biomarker

Also Published As

Publication number Publication date
RU2019121145A (ru) 2021-02-12
RU2763311C2 (ru) 2021-12-28
KR20190104568A (ko) 2019-09-10
RU2019121145A3 (es) 2021-04-26
MY195253A (en) 2023-01-11
CN110177561B (zh) 2023-09-12
AU2018207946A1 (en) 2019-07-25
JP2020513780A (ja) 2020-05-21
EP3568144A1 (en) 2019-11-20
EP3568144B1 (en) 2024-05-08
JP7089523B2 (ja) 2022-06-22
US11166993B2 (en) 2021-11-09
BR112019014418A2 (pt) 2020-04-14
CA3049624A1 (en) 2018-07-19
EP3568144C0 (en) 2024-05-08
WO2018130667A1 (en) 2018-07-19
MX2019008292A (es) 2019-09-16
KR102500496B1 (ko) 2023-02-16
US20190358275A1 (en) 2019-11-28
PH12019501629A1 (en) 2020-06-01
CN110177561A (zh) 2019-08-27
AU2018207946B2 (en) 2024-07-18

Similar Documents

Publication Publication Date Title
EA202091389A1 (ru) Композиция на основе пробиотиков и её применение
BR112015025256A8 (pt) Cepas probióticas para uso no tratamento ou prevenção da osteoporose
AR110684A1 (es) Composiciones que comprenden cepas bacterianas y método de tratamiento
CL2012000869A1 (es) Composicion que comprende cepa seleccionada de lactobacillus plantarum cect 7527, o cepas mutantes de la misma; uso de una composicion para prevenir y/o tratar transtornos cardiovasculares.
PE20210322A1 (es) Composiciones que comprenden microbiota coseleccionada y metodos para su uso
CL2018001936A1 (es) Nueva cepa bacteriana probiótica de lactobacillus plantarum y composiciones y usos de la misma en el tratamiento de la inflamación.
BR112018003123A2 (pt) composição, enema, cepa isolada, método para tratamento e/ou prevenção de uma condição gastrointestinal, e, uso de uma composição, de um enema ou de uma ou mais de uma cepa bacteriana isolada
AR107921A1 (es) Uso de probióticos en el tratamiento y/o la prevención de la enfermedad de la psoriasis
BR112016000072A2 (pt) composições orais
MX2017014245A (es) Composiciones que comprenden celulas germinales mesenquimales y usos de las mismas.
CO2017007338A2 (es) Composición que comprende dos cepas de las especies microbianas lactobacillus rhamnosus y bifidobacterium longum capaces de incrementar la fertilidad masculina
BR112018072511A2 (pt) métodos para selecionar uma cepa bacteriana e para profilaxia, inibição e/ou tratamento de uma alergia, cepa, e, composição antialérgica
BR112019001919A2 (pt) composição de tratamento de superfícies rígidas, método para fornecer o brilho da superfície e utilização da composição
BR112018070512A2 (pt) composição, usos de uma composição e método para aumentar a massa corporal magra
BR112017023636A2 (pt) suplemento dietético
BR112021020617A2 (pt) Composições probióticas e usos das mesmas
MX2017013278A (es) Odorante osmanthus.
CL2019001938A1 (es) Composiciones probióticas y usos de las mismas.
PH12020550104A1 (en) Salts of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
CO2018001271A2 (es) Composición microbiana de microorganismos probióticos
BR112018071493A2 (pt) usos de ácido linoleico (la) e ácido alfa-linolênico (ala) na fabricação de uma composição nutricional, composição nutricional, método para prevenir declínio no funcionamento cognitivo induzido e método para prevenir redução na neurogênese induzida por estresse precoce
CO2020009424A2 (es) Composición que comprende nuevas cepas de lactobacillus salivarius y método para la prevención y el tratamiento de otitis e infecciones respiratorias de vías altas
BR112015032351A2 (pt) composição compreendendo l. rhamnosus gg
PL416198A1 (pl) Kompozycja farmaceutyczna zawierająca połączenie kwasu hialuronowego i roślinnych fitoestrogenów do aplikacji waginalnej
AR112592A1 (es) Composiciones que comprenden cepas bacterianas, métodos